락토바실루스 가세리 관련 위식도 역류질환(GERD)
D 연구 예비 연구(실험실 연구, 증례 보고)만 존재합니다.일본 연구의 새로운 근거입니다. 산 관련 증상을 줄일 수 있습니다. 서구 인구에서는 아직 재현되지 않았습니다.
<\/script>\n`;
},
get iframeSnippet() {
const domain = 'gutcited.com';
const params = 'ingredient\u003Dlactobacillus\u002Dgasseri\u0026condition\u003Dgerd';
return ``;
},
get activeSnippet() {
return this.method === 'script' ? this.scriptSnippet : this.iframeSnippet;
},
copySnippet() {
navigator.clipboard.writeText(this.activeSnippet).then(() => {
this.copied = true;
setTimeout(() => { this.copied = false; }, 2000);
});
}
}"
@keydown.escape.window="open = false"
@click.outside="open = false">
D
결론
일본 연구의 새로운 근거입니다. 산 관련 증상을 줄일 수 있습니다. 서구 인구에서는 아직 재현되지 않았습니다.
Key Study Findings
Meta-Analysis
Strain-Specific Systematic Review with Meta-Analysis of Probiotics Efficacy in the Treatment of Irritable Bowel Syndrome.
Dose: None
vs: placebo
Outcome: improvement in key IBS symptoms
효과: None
None
대상 집단: patients with IBS from 32 RCTs evaluating 10 probiotic strains
In Vitro
Lactobacillus gasseri suppresses the Helicobacter pylori-induced expression of the proliferation-associated factors HBEGF and TGF-α in …
Dose: None
vs: H. pylori infection without lactobacilli
Outcome: ADAM17, HBEGF, TGF-alpha expression
효과: None
None
대상 집단: AGS gastric epithelial cells and mouse model
In Vitro
The modulatory effect of Lactobacillus gasseri ATCC 33323 on autophagy induced by extracellular vesicles of …
Dose: 50 μg/ml
vs: None
Outcome: Inflammatory markers
효과: None
None
대상 집단: None
Other
Effect of Lactobacillus gasseri BIO6369 and Lacticaseibacillus rhamnosus BIO5326 on Gastric Carcinogenesis Induced by Helicobacter …
Dose: None
vs: None
Outcome: Inflammatory markers
효과: None
None
대상 집단: Cancer patients
In Vitro
Effects of Glutamine, Curcumin and Fish Bioactive Peptides Alone or in Combination on Intestinal Permeability …
Dose: None
vs: None
Outcome: inflammation markers
효과: None
None
대상 집단: Mice
Case-Control
n=178
Oral and gastric microbiome in relation to gastric intestinal metaplasia.
Dose: None
vs: None
Outcome: Oral/gastric microbiome associations with IM
효과: None
None
대상 집단: Gastric intestinal metaplasia cases and matched controls
Key Statistics
3
연구
300
참여자
↑
Positive
D
등급
Referenced Papers
Journal of clinical …
2026
International journal of …
2025
Microbial pathogenesis
2024
8 인용
Helicobacter
2024
5 인용
International journal of …
2023
9 인용
International journal of …
2022
59 인용
BMC microbiology
2022
28 인용
Food & function
2022
19 인용
Probiotics and antimicrobial …
2021
30 인용
Comparative immunology, microbiology …
2019
72 인용
BMJ open gastroenterology
2019
14 인용
Digestion
2017
67 인용
Gastroenterology research and …
2016
38 인용
Helicobacter
2015
26 인용
PloS one
2014
171 인용
Frontiers in microbiology
2014
78 인용
Genomic and phenotypic evidence for probiotic influences of Lactobacillus gasseri on human health.
Review
FEMS microbiology reviews
2013
196 인용
Journal of food …
2012
56 인용
Journal of clinical …
2012
37 인용
Letters in applied …
2010
126 인용
Journal of medicinal …
2010
19 인용
Probiotics and antimicrobial …
2010
9 인용
Helicobacter
2009
48 인용
Cellular microbiology
2006
50 인용
Letters in applied …
2006
26 인용
Journal of gastroenterology …
2003
77 인용
The Journal of …
2001
309 인용
Dosage & Usage
mg = milligrams · mcg = micrograms (1,000× smaller) · IU = International Units
일반적으로 사용되는 용량
- general:
- 1-10 billion CFU/day
- gerdsupport:
- 1-5 billion CFU/day
- hpylorisupport:
- 100 million CFU/day (LG21 strain, yogurt form) for 8-12 weeks
상한량: Well-tolerated up to 10 billion CFU/day in clinical trials
연구에서 사용된 용량
| 용량 | 기간 | 효과 | N |
|---|---|---|---|
| None | -- | Positive | -- |
| None | -- | Positive | -- |
| 50 μg/ml | -- | Mixed | -- |
| None | -- | Positive | -- |
| None | -- | Mixed | -- |
| None | -- | Neutral | 178 |
| None | -- | Positive | -- |
| None | -- | Positive | -- |
권장 복용 시간: Before meals or with meals; yogurt form taken with food
Safety & Side Effects
보고된 부작용
- ⚠ Mild gas during initial use
- ⚠ Occasional loose stools
- ⚠ Rare abdominal discomfort
- ⚠ Very rare: bacteremia in immunocompromised individuals
알려진 상호작용
- ● Antibiotics (may reduce probiotic viability; space dosing 2 hours apart)
- ● Proton pump inhibitors (altered gastric pH may affect colonization)
- ● Immunosuppressants (theoretical risk in immunocompromised patients)
일일 최대 섭취 허용량: Well-tolerated up to 10 billion CFU/day in clinical trials
건강기능식품을 복용하기 전에 반드시 의료 전문가와 상담하십시오.
Frequently Asked Questions
Does 락토바실루스 가세리 help with 위식도 역류질환(GERD)?
Based on 3 studies with 300 participants, there is preliminary evidence that needs more research that 락토바실루스 가세리 may support 위식도 역류질환(GERD) management. Our evidence grade is D (Very Early Research).
How much 락토바실루스 가세리 should I take for 위식도 역류질환(GERD)?
Studies have used various dosages. A commonly studied range is 1-10 billion CFU/day. Always consult your healthcare provider before starting any supplement regimen.
Are there side effects of 락토바실루스 가세리?
Reported side effects may include Mild gas during initial use, Occasional loose stools, Rare abdominal discomfort, Very rare: bacteremia in immunocompromised individuals. Most side effects are mild and dose-dependent. Consult your doctor if you experience any adverse reactions.
How strong is the evidence for 락토바실루스 가세리 and 위식도 역류질환(GERD)?
We rate the evidence as Grade D (Very Early Research). This rating is based on 3 peer-reviewed studies with 300 total participants. The overall direction of effect is positive.
Related Evidence
관련 다른 성분: 위식도 역류질환(GERD)
락토바실루스 가세리 다른 건강 상태에 대한 근거
References
- [1] Roman Maslennikov et al.. J Clin Med. 2026. Strain-Specific Systematic Review with Meta-Analysis of Probiotics Efficacy in the Treatment of Irritable Bowel Syndrome. doi:10.3390/jcm15031152 PubMed
- [2] Tanvi Somiah et al.. Int J Med Microbiol. 2025. Lactobacillus gasseri suppresses the Helicobacter pylori-induced expression of the proliferation-associated factors HBEGF and TGF-α in gastric host cells. doi:10.1016/j.ijmm.2025.151694 PubMed
- [3] Zahra Sadeghloo et al.. Microb Pathog. 2024. The modulatory effect of Lactobacillus gasseri ATCC 33323 on autophagy induced by extracellular vesicles of Helicobacter pylori in gastric epithelial … doi:10.1016/j.micpath.2024.106559 PubMed
- [4] Marine Jauvain et al.. Helicobacter. 2024. Effect of Lactobacillus gasseri BIO6369 and Lacticaseibacillus rhamnosus BIO5326 on Gastric Carcinogenesis Induced by Helicobacter pylori Infection. doi:10.1111/hel.13108 PubMed
- [5] Ludovic D Langlois et al.. Int J Mol Sci. 2023. Effects of Glutamine, Curcumin and Fish Bioactive Peptides Alone or in Combination on Intestinal Permeability in a Chronic-Restraint Stress Model. doi:10.3390/ijms24087220 PubMed
- [6] Fen Wu et al.. Int J Cancer. 2022. Oral and gastric microbiome in relation to gastric intestinal metaplasia. doi:10.1002/ijc.33848 PubMed
- [7] Tran Thi Dieu Thuy et al.. BMC Microbiol. 2022. Anti-Helicobacter pylori activity of potential probiotic Lactiplantibacillus pentosus SLC13. doi:10.1186/s12866-022-02701-z PubMed
- [8] Yuyang Zhao et al.. Food Funct. 2022. Two novel lactic acid bacteria, Limosilactobacillus fermentum MN-LF23 and Lactobacillus gasseri MN-LG80, inhibited Helicobacter pylori infection in C57BL/6 mice. doi:10.1039/d2fo02034c PubMed
- [9] Mahdieh Yarmohammadi et al.. Probiotics Antimicrob Proteins. 2021. Effects of a Potential Probiotic Strain Lactobacillus gasseri ATCC 33323 on Helicobacter pylori-Induced Inflammatory Response and Gene Expression in Coinfected … doi:10.1007/s12602-020-09721-z PubMed
- [10] Majid Eslami et al.. Comp Immunol Microbiol Infect Dis. 2019. Are probiotics useful for therapy of Helicobacter pylori diseases? doi:10.1016/j.cimid.2019.02.010 PubMed
- [11] Yasuhiro Koga et al.. BMJ Open Gastroenterol. 2019. Probiotic L. gasseri strain (LG21) for the upper gastrointestinal tract acting through improvement of indigenous microbiota. doi:10.1136/bmjgast-2019-000314 PubMed
- [12] Toshihiro Ohtsu et al.. Digestion. 2017. The Ameliorating Effect of Lactobacillus gasseri OLL2716 on Functional Dyspepsia in Helicobacter pylori-Uninfected Individuals: A Randomized Controlled Study. doi:10.1159/000479000 PubMed
- [13] Atsushi Takagi et al.. Gastroenterol Res Pract. 2016. Effects of Lactobacillus gasseri OLL2716 on Helicobacter pylori-Associated Dyspepsia: A Multicenter Randomized Double-Blind Controlled Trial. doi:10.1155/2016/7490452 PubMed
- [14] Hidenori Matsui et al.. Helicobacter. 2015. Mouse Models for Assessing the Protective Efficacy of Lactobacillus gasseri SBT2055 against Helicobacter suis Infection Associated with the Development of … doi:10.1111/hel.12203 PubMed
- [15] Yini Dang et al.. PLoS One. 2014. The effect of probiotics supplementation on Helicobacter pylori eradication rates and side effects during eradication therapy: a meta-analysis. doi:10.1371/journal.pone.0111030 PubMed
- [16] Susana Delgado et al.. Front Microbiol. 2014. Probiotic and technological properties of Lactobacillus spp. strains from the human stomach in the search for potential candidates against gastric … doi:10.3389/fmicb.2014.00766 PubMed
- [17] Kurt Selle et al.. FEMS Microbiol Rev. 2013. Genomic and phenotypic evidence for probiotic influences of Lactobacillus gasseri on human health. doi:10.1111/1574-6976.12021 PubMed
- [18] Xiaohua Chen et al.. J Food Sci. 2012. Antagonistic activities of lactobacilli against Helicobacter pylori growth and infection in human gastric epithelial cells. doi:10.1111/j.1750-3841.2011.02498.x PubMed
- [19] Shigeru Fujimura et al.. J Clin Microbiol. 2012. Probiotic mechanism of Lactobacillus gasseri OLL2716 strain against Helicobacter pylori. doi:10.1128/JCM.06262-11 PubMed
- [20] M Kawase et al.. Lett Appl Microbiol. 2010. Oral administration of lactobacilli from human intestinal tract protects mice against influenza virus infection. doi:10.1111/j.1472-765X.2010.02849.x PubMed
- [21] Yuko Kato-Mori et al.. J Med Food. 2010. Fermentation metabolites from Lactobacillus gasseri and Propionibacterium freudenreichii exert bacteriocidal effects in mice. doi:10.1089/jmf.2010.1137 PubMed
- [22] Luc De Vuyst et al.. Probiotics Antimicrob Proteins. 2010. Peptide Extracts from Cultures of Certain Lactobacilli Inhibit Helicobacter pylori. doi:10.1007/s12602-009-9029-4 PubMed
- [23] Surasak Boonyaritichaikij et al.. Helicobacter. 2009. Long-term administration of probiotics to asymptomatic pre-school children for either the eradication or the prevention of Helicobacter pylori infection. doi:10.1111/j.1523-5378.2009.00675.x PubMed
- [24] Takeshi Shimosato et al.. Cell Microbiol. 2006. Strong immunostimulatory activity of AT-oligodeoxynucleotide requires a six-base loop with a self-stabilized 5'-C...G-3' stem structure. doi:10.1111/j.1462-5822.2005.00640.x PubMed
- [25] S Fujimura et al.. Lett Appl Microbiol. 2006. Detection of Lactobacillus gasseri OLL2716 strain administered with yogurt drink in gastric mucus layer in humans. doi:10.1111/j.1472-765X.2006.02017.x PubMed
- [26] Atsushi Ushiyama et al.. J Gastroenterol Hepatol. 2003. Lactobacillus gasseri OLL2716 as a probiotic in clarithromycin-resistant Helicobacter pylori infection. doi:10.1046/j.1440-1746.2003.03102.x PubMed
- [27] I Sakamoto et al.. J Antimicrob Chemother. 2001. Suppressive effect of Lactobacillus gasseri OLL 2716 (LG21) on Helicobacter pylori infection in humans. doi:10.1093/jac/47.5.709 PubMed
FDA 면책 조항: 이 내용은 미국 식품의약국(FDA)의 평가를 받지 않았습니다. 이 웹사이트의 제품 및 정보는 질병의 진단, 치료, 완치 또는 예방을 목적으로 하지 않습니다. 제시된 근거 등급은 발표된 동료 심사 연구에 대한 우리의 분석에 기반하며, 의학적 조언을 구성하지 않습니다. 건강기능식품 복용을 시작하기 전에 반드시 의료 전문가와 상담하십시오.